UBS Group AG Buys 580,765 Shares of Clarivate PLC $CLVT

UBS Group AG boosted its stake in shares of Clarivate PLC (NYSE:CLVT) by 21.6% in the fourth quarter, Holdings Channel reports. The firm owned 3,271,921 shares of the company’s stock after acquiring an additional 580,765 shares during the period. UBS Group AG’s holdings in Clarivate were worth $10,928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its position in Clarivate by 3.3% during the third quarter. Dimensional Fund Advisors LP now owns 21,768,783 shares of the company’s stock worth $83,373,000 after purchasing an additional 696,903 shares during the period. American Century Companies Inc. boosted its position in Clarivate by 20.6% during the third quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock worth $38,200,000 after purchasing an additional 1,706,306 shares during the period. Vanguard Group Inc. boosted its position in Clarivate by 9.3% during the third quarter. Vanguard Group Inc. now owns 8,922,585 shares of the company’s stock worth $34,173,000 after purchasing an additional 756,722 shares during the period. Balyasny Asset Management L.P. boosted its position in Clarivate by 827.6% during the third quarter. Balyasny Asset Management L.P. now owns 4,882,593 shares of the company’s stock worth $18,700,000 after purchasing an additional 4,356,232 shares during the period. Finally, Man Group plc boosted its position in Clarivate by 228.1% during the second quarter. Man Group plc now owns 3,091,139 shares of the company’s stock worth $13,292,000 after purchasing an additional 2,148,943 shares during the period. Institutional investors own 85.72% of the company’s stock.

Clarivate Stock Performance

Shares of NYSE CLVT opened at $2.43 on Friday. The business has a fifty day simple moving average of $2.54 and a 200 day simple moving average of $2.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -11.55 and a beta of 1.41. Clarivate PLC has a one year low of $1.66 and a one year high of $4.77.

Clarivate (NYSE:CLVT) last issued its earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. The business had revenue of $585.50 million during the quarter, compared to analyst estimates of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.Clarivate’s revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Sell-side analysts expect that Clarivate PLC will post 0.65 EPS for the current year.

Analyst Upgrades and Downgrades

CLVT has been the subject of a number of recent analyst reports. Citigroup decreased their target price on Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research report on Friday, March 27th. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays reduced their price objective on Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada reduced their price objective on Clarivate from $5.00 to $3.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 25th. Five research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Clarivate has an average rating of “Reduce” and an average price target of $3.22.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.